MSI is a company limited by guarantee, incorporated and registered in England and Wales, and is also registered as a charity.
In pursuit of a world where everyone has the right to determine their own future, we provide services in 37 countries through branches and other not for profit companies and organisations which form part of our global partnership.
From our international support office in central London, we support and oversee the impact of our members by setting the strategy, standards and policies for the global partnership. We also provide technical assistance, research and monitoring and promote and fundraise for the global partnership. In keeping with our mission, we focus on creating the conditions that enable the provision of quality services, which are sustainable and reach as many people as possible.
Our UK division has a separate management structure, and provides abortion and other reproductive and sexual health services in the UK through a network of clinics.
The MSI Board of Trustees makes decisions on major issues facing the partnership including in the areas of: strategic direction, clinical practices, polices and processes, financial management and institutional integrity. The Board also has various subcommittees, for example the Audit Committee and Global Quality Governance Committee, that focus on high priority areas.
The Board of Trustees is made up of individuals who are leaders in their field, committed to the organisation’s mission. They bring skill, diversity, energy, and experience to MSI. Their backgrounds include senior level experience in the commercial health sector; clinical and teaching experience in women’s reproductive health; leadership in the charity sector; business; government; and advocacy.
The Executive Team, based in our support office in London, is responsible for implementing strategy and the day-to-day operations that enable the partnership to meet its mission and goals. The Executive Team is led by the Chief Executive Officer who reports to the Board of Trustees.
You can find out more about our Board members and Executive Team on the People page.
In March 2019, MSI Reproductive Choices became a participant of the UN Global Compact (UNGC) under our former name Marie Stopes International and our first Communication on Engagement was published in March 2021.
The UNGC is the world's largest corporate sustainability initiative and aims to mobilise a global movement of companies and stakeholders to create a more sustainable world. It is a call to do business responsibly, by aligning strategies and operations with Ten Principles on human rights, labour, environment and anti-corruption; and to collaborate and innovate to advance broad societal goals such as the Sustainable Development Goals.
Our commitment to the UNGC will see MSI:
As a health care provider and advocate for human rights, MSI recognises that gender inequality impacts an individual’s needs, choices and access to health information and services. Understanding inequalities and the power relations that exist within families, communities and wider societies is essential to developing programmes that increase access to services, improve reproductive health outcomes and reduce stigma.Read more about our commitment to gender equality
The quality of our services is fundamental to the safety and well-being of every single one of our clients. With this in mind we set rigorous standards and have the following systems in place to check and maintain consistently high quality across all our international programmes. You can find out more about our Global Medical Development Team here.
QTA is a quality audit that covers a sample of service locations and teams within each country programme once a year. This is conducted by Global Medical Development Team (MDT) members, trained clinical quality staff from other programmes, or MDT-approved external consultants.
A quality audit covering a sample of service locations and teams within each country programme once a year. This is conducted by MDT, trained clinical quality staff from another programme, or MDT-approved external consultants
A ‘QTA-like’ clinical quality audit that several selected country programmes receive each year. These are carried out by Global MDT members in programmes that did not receive an external QTA by Global MDT members that year.
A senior leadership team within each country programme, led by the head of clinical services and including the country director. The Medical Advisory Team (MAT) in each country programme meets once every quarter to discuss key issues related to clinical quality and client safety. The meetings follow a standard agenda and the minutes are sent to the Global MDT.
A standard report that captures key clinical quality and clinical governance indicators that each country programme is required to submit quarterly. The reports are compiled by the clinical service leads of each country programme and are submitted through International Operations reporting systems. The minutes of the last MAT meeting is submitted together with these reports.
All country programmes service providers are expected to report clinical incidents in line with a standard reporting system. Incidents are categorised into ‘red’, ‘amber’, and ‘green’ based on severity. ‘Red’ or critical incidents are reported to the Medical Director within 24 hours of the incident.
‘Amber’ and ‘green’ incidents are reported to the senior management of each programme. Critical incidents are reviewed by a panel of Global MDT members and lessons shared across the partnership. ‘Amber’ and ‘green’ incidents are handled at country programme level. Incidents are a key item discussed during the MAT meetings.
All country programmes report product-related incidents to MDT. These incidents are investigated by the senior pharmaceutical adviser in collaboration with clinical leads and other MDT members. Corrective measures are taken and reporting to manufacturers done where needed. Learning is shared across the partnership.
This is a system that calculates estimated clinical risk within different channels based on service types provided, service numbers, and selected control indicators. With no extra data burden to country programmes, the system is able to highlight higher-risk channels by country, and allows MDT and Operations to recognise and mitigate potential sources of clinical risk.
A product quality assurance tool that allows MSI to confirm that ‘Key-SRH’ commodities in country programmes come from quality sources of established quality. The system requires country programmes to input information on selected drugs and other items on a regular basis.
These tools are expected in all country programmes:
MSI’s Code of Conduct outlines organisational and team member commitments to professional ethics client care and building an inclusive organisational culture which promotes equality of opportunity. MSI expects all programmes and team members to work with honesty and integrity; upholding existing commitments to safeguarding, data-protection, anti-modern slavery and anti-fraud and bribery, including a requirement to declare any personal or other close relationships and conflicts of interest.
MSI also expects its Business partners to share its ethical and business principles, and to promote these principles to their suppliers, sub-contractors, and business partners. Read more about these principles in MSI’s Code of Conduct for Business Partners.MSI Code of Conduct 2021 MSI Business Partner Code of Conduct 2021
Gender equality is foundational to our mission, and we are fully committed to ensuring that there are no barriers or biases in place at MSI that deny equality of opportunity to women or any other group in society.
As an organisation, we remain committed to reducing the gender pay gap and are focused on supporting women into more senior leadership roles and on making fundamental and sustainable changes to make MSI a more diverse and inclusive employer.